Alcon Inc. and LENSAR, Inc. announced that they are terminating the merger agreement that had been announced earlier in the year. The deal, which had been valued at approximately $356 million, is now cancelled, ending Alcon’s planned expansion into advanced robotic cataract laser technology.
The termination was driven by regulatory and strategic considerations. LENSAR stated that the Federal Trade Commission had indicated it would seek an injunction against the acquisition, making U.S. regulatory approval unlikely before the merger’s outside dates. Alcon’s CEO, David Endicott, cited the delay and associated costs of the FTC review as making the transaction unattractive.
The cancellation removes the $356 million transaction from Alcon’s balance sheet and future earnings projections. Alcon will no longer receive the projected synergies or market‑share gains that were expected from integrating LENSAR’s robotic laser platform. LENSAR will remain an independent company, retaining the $10 million deposit that Alcon had provided as part of the termination agreement.
Investors reacted negatively to the termination. LENSAR’s shares fell sharply after the announcement, while Alcon’s shares experienced a modest decline. The market reaction was driven by the loss of a significant acquisition opportunity for Alcon and the loss of a potential exit for LENSAR.
Alcon’s CEO emphasized that the company still believes the acquisition would have significantly enhanced FLACS innovation and competition. However, the extended regulatory review and associated costs have made the transaction unattractive to pursue further. Alcon’s guidance for 2026 remains unchanged, with expectations of 5%–7% net‑sales growth and 9%–12% core EPS growth.
LENSAR will continue to focus on its ALLY Robotic Cataract Laser System, which received FDA clearance in 2022 and European approval. The company plans to provide a strategic update on March 31, 2026, when it releases its fourth‑quarter and full‑year 2025 financial results.
The termination underscores the FTC’s focus on maintaining competition in the medical equipment market, particularly for advanced surgical systems. It also highlights the challenges of pursuing large cross‑border acquisitions in a highly regulated industry, where regulatory approval can become a decisive factor in the viability of a deal.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.